Cost-Effectiveness Of Drug Compliance In Type 2 Diabetes Mellitus Patients

Página do item simplificado
dc.contributor.authorMaciel, Olga
dc.contributor.authorVera, Zully
dc.contributor.authorMarin, Gustavo H.
dc.contributor.authorMorinigo, Macarena
dc.contributor.authorMaidana, Mabel
dc.contributor.authorMastroianni, Patricia [UNESP]
dc.contributor.institutionNatl Univ Asuncion
dc.contributor.institutionNatl Univ La Plata
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2019-10-03T18:19:18Z
dc.date.available2019-10-03T18:19:18Z
dc.date.issued2018-09-01
dc.description.abstractType 2 diabetes mellitus affects 15% of the population around the world, causing health complications and increasing the treatment's costs. Being a chronic outpatient treatment disease, patient compliance is higher importance to achieve therapeutic success. The present study measure the cost effectiveness of the compliance of this disease. An observational, cross-sectional, pharmaco-economic study was performed. A National program to stimulate treatment adherence was taken as intervention stage. Compliance was measure by Morisky-Green test and details of the events in each patient's health (medication, consultations, hospitalization and concomitant treatments) were used to determinate the direct costs for Ministry of Public Health. Effectiveness was measured by percentage of glycated hemoglobin (HbA1c). The sample obtained was 55 patients, which were grouped into 31 compliant and 24 non-compliant. The cost-effectiveness of compliance was 466 US$ / compliant effective patient and 1,807 US$ / non-compliant effective patient. The cost-effectiveness of hypoglycemic drug therapy compliance is significantly lower (almost 4 times) than non-compliance. Type 2 Diabetes Mellitus patients that have no therapy adherence are not able to maintain protective levels of HbA1c. In addition, for the Ministry of Public Health, the lack of adherence requires more budget to accomplished the health goals.en
dc.description.affiliationNatl Univ Asuncion, Dept Pharm, Fac Chem Sci, Mcal Estigarribia Km 11,5 Campus Univ, San Lorenzo, Paraguay
dc.description.affiliationNatl Univ La Plata, CONICET, RA-1900 La Plata, Buenos Aires, Argentina
dc.description.affiliationUniv Estadual Paulista, Sch Pharmaceut Sci, Av Jose Bonifacio1970, BR-14801 Araraquara, SP, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, Sch Pharmaceut Sci, Av Jose Bonifacio1970, BR-14801 Araraquara, SP, Brazil
dc.description.sponsorshipNational Diabetes Program
dc.description.sponsorshipMinistry of Health
dc.format.extent1824-1829
dc.identifier.citationResearch Journal Of Pharmaceutical Biological And Chemical Sciences. Proddatur: Rjpbcs Research Journal Pharmaceutical, Biological & Chemical Sciences, v. 9, n. 5, p. 1824-1829, 2018.
dc.identifier.issn0975-8585
dc.identifier.urihttp://hdl.handle.net/11449/184011
dc.identifier.wosWOS:000447016800230
dc.language.isoeng
dc.publisherRjpbcs Research Journal Pharmaceutical, Biological & Chemical Sciences
dc.relation.ispartofResearch Journal Of Pharmaceutical Biological And Chemical Sciences
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectCost-effectiveness
dc.subjectadherence
dc.subjectpharmacotherapy compliance
dc.subjectType 2 Diabetes Mellitus
dc.titleCost-Effectiveness Of Drug Compliance In Type 2 Diabetes Mellitus Patientsen
dc.typeArtigo
dcterms.rightsHolderRjpbcs Research Journal Pharmaceutical, Biological & Chemical Sciences
unesp.author.orcid0000-0001-8467-7278[6]

Arquivos

Coleções

Artigos